Table 1.
Clinical and Pathologic Characteristics of HCC Patients
| Patient | Tumor biopsy code | Cell number, 106 |
Edmondson–Steiner grade, I–IV | TIM | Intratumoral TIL, % |
Stroma TIL, % |
Time point | Sex | YOB | BCLC | Cirrhosis | Liver Disease | AFP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D403 | 4.5 | II | 3 | 0 | 0 | Pretreatment | M | 1944 | A | No | NAFLD | 9.5 |
| 2 | D214 | 20 | II | 2 | 0 | 30 | Pretreatment | M | 1944 | A | Yes | ALD | 7.2 |
| 3 | D316 | 3.5 | II | 3 | 0 | 0 | Pretreatment | M | 1932 | A | No | NAFLD | 1 |
| 4 | D373 | 7.5 | II | 2 | 5 | 30 | Pretreatment | F | 1938 | A | No | HEP C | 5.6 |
| 4 | D557 | 2.5 | III | 1 | 20 | 20 | Nivolumab | F | 1938 | A | No | HEP C | 5.6 |
| 5 | D143 | 2 | III | 1 | 20 | 20 | Pretreatment | F | 1954 | D | Yes | ALD | 6 |
| 6 | D330 | 30 | II | 1 | 10 | 20 | Pretreatment | M | 1938 | C | Yes | ALD | 48 |
| 6 | D448 | 1.4 | II | 1 | 10 | 30 | Nivolumab | M | 1938 | C | Yes | ALD | 48 |
| 7 | D096 | 3.5 | IV | 1 | 20 | 20 | Pretreatment | M | 1941 | A | No | ALD | 2 |
| 8 | D324 | 10 | III | 1 | 10 | 20 | Pretreatment | M | 1959 | D | Yes | ALD | 104,710 |
| 9 | D332 | 3.6 | II | 1 | 10 | 20 | Pretreatment | M | 1945 | A | No | ALD | 3.1 |
| 10 | D359 | 18 | III | 1 | 20 | NA | Pretreatment | M | 1930 | B | No | ALD and NAFLD | 5917 |
| 11 | D147 | 4.5 | III | 1 | 10 | 10 | Pretreatment | M | 1948 | A | No | HEP B | 32.5 |
| 12 | D562 | 2.5 | II | 2 | 5 | 30 | Pretreatment | M | 1943 | A | Yes | HEP C | 2.5 |
| 13 | D304 | NA | III | 3 | 5 | 0 | Pretreatment | M | 1953 | A | No | HEP C and ALD | NA |
| 14 | D588 | 2.5 | II | 3 | 0 | 0 | Pretreatment | M | 1932 | A | No | NAFLD | 338 |
| 15 | D565 | 5 | IV | 1 | 20 | 5 | Pretreatment | M | 1974 | C | No | NAFLD | 645 |
| 16 | D274 | 1.6 | III | 1 | 10 | 10 | Pretreatment | M | 1936 | A | Yes | NAFLD | 1.3 |
| 17 | D029 | 2 | II | 2 | 0 | 40 | Pretreatment | F | 1943 | B | Yes | ALD | 7.9 |
| 18 | D113 | 0.8 | III | 1 | 10 | 30 | Pretreatment | M | 1937 | A | No | ALD and NAFLD | 49.8 |
| 18 | D386 | 6 | III | 1 | 30 | 20 | Pretreatment | M | 1937 | A | No | ALD and NAFLD | 49.8 |
| 18 | D388 | 1.2 | III | 1 | 30 | 20 | Pretreatment | M | 1937 | A | No | ALD and NAFLD | 49.8 |
| 19 | D336 | 18 | II | 3 | 5 | 0 | Pretreatment | M | 1936 | C | Yes | ALD | 6.6 |
| 19 | D572 | 2 | II | 1 | 10 | 10 | Nivolumab | M | 1936 | C | Yes | ALD | 6.6 |
| 19 | D573 | 2.5 | II | 3 | 0 | 0 | Nivolumab | M | 1936 | C | Yes | ALD | 6.6 |
| 20 | D268 | 30 | II | 1 | 20 | NA | Pretreatment | M | 1946 | B | Yes | ALD and NAFLD | 10.2 |
| 21 | D240 | 60 | II | 3 | 5 | 5 | Pretreatment | M | 1944 | B | Yes | ALD and NAFLD | 5.6 |
| 22 | D228 | 60 | II | 1 | 10 | 20 | Pretreatment | M | 1936 | A | Yes | ALD | 3.6 |
| 23 | D483 | 1.2 | II | 1 | 20 | 20 | Pretreatment | M | 1934 | A | No | ALD and NAFLD | 2.7 |
| 24 | D176 | 40 | II | 3 | 0 | 0 | Pretreatment | M | 1937 | C | No | NAFLD | 0.9 |
| 25 | D020 | NA | III | 1 | 30 | 5 | Pretreatment | F | 1945 | C | Yes | ALD | 1745 |
| 26 | D302 | 150 | III | 1 | 30 | 20 | Pretreatment | F | 1949 | C | Yes | ALD | 400,000 |
| 27 | D158 | 18 | II | 2 | 0 | 30 | Pretreatment | F | 1939 | B | Yes | NAFLD | 4.6 |
| 28 | D156 | 60 | II | NA | 5 | NA | Pretreatment | M | 1949 | A | Yes | HEP B | 2 |
| 29 | D017 | NA | III | NA | 5 | NA | Pretreatment | M | 1933 | A | No | ALD | 231 |
| 30 | D045 | 1.5 | III | 3 | 0 | 5 | Pretreatment | M | 1947 | A | Yes | HEP C | 7852 |
| 31 | D135 | 1.9 | IV | 1 | 10 | 30 | Pretreatment | M | 1959 | C | Yes | HEP C | 11.4 |
| 32 | D200 | 21 | II | 3 | 0 | 0 | Pretreatment | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 32 | D201 | 30 | III | 1 | 20 | NA | Pretreatment | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 32 | D202 | 20 | II | 3 | 0 | NA | Pretreatment | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 32 | D318 | 4 | II | 3 | 0 | 5 | Pretreatment | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 32 | D319 | 2.7 | II | 3 | 0 | 0 | Pretreatment | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 32 | D505 | NA | III | NA | 0 | NA | Nivolumab | M | 1940 | B | No | ALD and NAFLD | 1615 |
| 33 | D503 | NA | III | 1 | 20 | 20 | Pretreatment | M | 1941 | B | No | NASH | 3995 |
| 34 | C948 | NA | III | 1 | 20 | 20 | Pretreatment | M | 1958 | C | Yes | HEP C and ALD | 12,054 |
| 34 | C949 | NA | III | 1 | 30 | 30 | Pretreatment | M | 1958 | C | Yes | HEP C and ALD | 12,054 |
| 34 | D001 | 1.7 | III | 1 | 30 | 30 | Nivolumab | M | 1958 | C | Yes | HEP C and ALD | 12,054 |
| 35 | D470 | NA | III | 1 | 20 | 10 | Nivolumab | M | 1958 | C | No | HEP C and NASH | 3.9 |
| 36 | D152 | 60 | II | 1 | 20 | 0 | Nivolumab | M | 1943 | B | No | HEP C | 1057 |
| 36 | D153 | 60 | I | 2 | 5 | 10 | Nivolumab | M | 1943 | B | No | HEP C | 1057 |
| 36 | D340 | 6 | II | 1 | 20 | 0 | Nivolumab | M | 1943 | B | No | HEP C | 1057 |
| 36 | D341 | 7 | I | 2 | 0 | 10 | Nivolumab | M | 1943 | B | No | HEP C | 1057 |
NOTE. For the tumor-immune microenvironment, 1 indicates immune-inflamed, 2 indicates immune-excluded, and 3 indicates immune-desert.
AFP, α-fetoprotein; ALD, alcoholic liver disease; BCLC, Barcelona Clinic Liver Cancer; HEP B, hepatitis B; HEP C, hepatitis C; NA, not applicable; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; TIM, tumor-immune microenvironment; YOB, year of birth.